Why direct-to-consumer drug ads deserve a closer look

What's new in pharma

September 12, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Let the rulemaking begin: Why direct-to-consumer drug ads deserve a closer look HHS Secretary Robert F. Kennedy Jr. plans to close what he calls a loophole that allows drugmakers to avoid sufficiently disclosing risk info By Ed Silverman FDA leaders moving to abandon advisory committee reviews of specific new drugs The agency "would like to get away" from assembling panels of experts to examine individual drugs, said a top official, George Tidmarsh By Arthur Allen — KFF Health News STAT+ | HHS to have Rensselaer investigate question of autism-vaccine link A much-investigated question about autism, dismissed in many studies, is getting a surge of new federal research money By Daniel Payne Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser